Department of Chemical and Petroleum Engineering, University of Pittsburgh, United States.
Department of Chemical and Petroleum Engineering, University of Pittsburgh, United States; Department of Bioengineering, University of Pittsburgh, United States; McGowan Institute for Regenerative Medicine, United States.
Curr Opin Biotechnol. 2019 Dec;60:250-258. doi: 10.1016/j.copbio.2019.05.011. Epub 2019 Aug 3.
Pluripotent stems cells (PSCs) can be expanded indefinitely and differentiated into almost any organ-specific cell type. This has enabled the generation of disease relevant tissues from patients in scalable quantities. iPSC-derived organs and organoids are currently being evaluated both in regenerative therapy which are proceeding towards clinical trials, and for disease modeling, which are facilitating drug screening efforts for discovery of novel therapeutics. Here we will review the current efforts and advances in iPSC technology and its subsequent applications and provide a brief commentary on future outlook of this promising technology.
多能干细胞(PSCs)可以无限扩增并分化为几乎任何器官特异性细胞类型。这使得能够从患者中以可扩展的数量产生与疾病相关的组织。目前正在对 iPSC 衍生的器官和类器官进行评估,既用于再生疗法(正在进行临床试验),也用于疾病建模(为发现新的治疗方法促进药物筛选)。在这里,我们将回顾 iPSC 技术的当前进展及其后续应用,并对这项有前途的技术的未来前景进行简要评论。